Molecular Partners
MOLN
6 hedge funds and large institutions have $5.6M invested in Molecular Partners in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 2 closing their positions.
0.03% more ownership
Funds ownership: 2.55% → 2.58% (+0.03%)
7% less capital invested
Capital invested by funds: $5.99M → $5.6M (-$392K)
25% less funds holding
Funds holding: 8 → 6 (-2)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$19.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$12.8K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2K |
| 4 |
Jane Street
New York
|
-$1.01K |
MOLN Hedge Fund Activity: Q1 2023 in Review
6 of the 6,282 institutional investors tracked by Wall St. Rank reported a position in Molecular Partners (MOLN) for Q1 2023, worth a combined $5.6M — down 6.5% from $5.99M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of MOLN and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Tang Capital Management, adding an estimated $104K. The largest seller was UBS Group, exiting entirely with an estimated $19.4K sold.
- 6 institutional investors held Molecular Partners (MOLN) as of Q1 2023, down from 8 in Q4 2022.
- Funds reported $5.6M of Molecular Partners stock for Q1 2023, down 6.5% quarter-over-quarter.
- 0 funds opened new Molecular Partners positions in Q1 2023 and 2 closed out, a net change of -2 holders.
- The largest Molecular Partners buyer in Q1 2023 was Tang Capital Management, an estimated $104K added.
- The largest Molecular Partners seller in Q1 2023 was UBS Group, an estimated $19.4K sold.
Based on aggregated 13F filings for Q1 2023.